-
Cipher Pharmaceuticals Inc. (CPH)
-
Aspen Aerogels Inc. (ASPN)
-
Duolingo Inc. (DUOL)
-
Cellebrite DI Ltd. (CLBT)
-
TransMedics Group Inc. (TMDX)
-
Flutter Entertainment Plc (FLUT)
Q: Hi 5i Team,
Would you still endorse a purchase of TMDX, CLBT, ASPN and CPH? When looking at the recent momentum of FLUT and DUOL would you still be buyers of these companies? What would be your order of preference if you were buying today?
Thanks as always,
Jon
Would you still endorse a purchase of TMDX, CLBT, ASPN and CPH? When looking at the recent momentum of FLUT and DUOL would you still be buyers of these companies? What would be your order of preference if you were buying today?
Thanks as always,
Jon
Q: After its huge drop Friday, CPH is down another 8% today. It said the failure of the clinical trials for Moberg's nail fungus medicine wouldn't impact sales or revenue "today" but how much was the market counting on this for the future? Does its failure really justify a 20% cut to CPH stock or is this way overdone?
Q: Share this news no queston
MISSISSAUGA, ON, Sept. 13, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015, a product for the treatment of nail fungus. Moberg has noted that the number of patients who have achieved clinical cure in this blinded subset of patients is lower than its expectations, which necessitates that Moberg inform the market about this fact.
Moberg's full press release can be found here.
Cipher owns the Canadian marketing rights to Moberg's MOB-015 through a licensing agreement (the "Agreement") dated September 18, 2018, to commercialize, promote, sell and distribute the product exclusively in Canada. On signing the Agreement, the Company paid an upfront amount of US$0.5 million and any future additional payments of up to US$14.1 million are contingent upon successful achievement of certain clinical data results as well as development, regulatory and commercial sales milestones. Cipher has no further financial obligations in respect of the Agreement if the applicable development and regulatory milestones outlined in the Agreement are not attained.
The Company will continue to collaborate with its partner Moberg as full results from their clinical trial become available, however this pipeline product does not impact the sales and earnings profile of Cipher's existing business today.
The Company continues to be focused on its recent acquisition of the NatrobaTM business from ParaPRO LLC as announced on July 29, 2024, as well as other potential growth opportunities. The Company believes the growth potential for the NatrobaTM product in the U.S. market and other markets internationally is significant, and the integration of this business into its existing profitable North American platform remains Cipher's focus and priority in the near term.
MISSISSAUGA, ON, Sept. 13, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015, a product for the treatment of nail fungus. Moberg has noted that the number of patients who have achieved clinical cure in this blinded subset of patients is lower than its expectations, which necessitates that Moberg inform the market about this fact.
Moberg's full press release can be found here.
Cipher owns the Canadian marketing rights to Moberg's MOB-015 through a licensing agreement (the "Agreement") dated September 18, 2018, to commercialize, promote, sell and distribute the product exclusively in Canada. On signing the Agreement, the Company paid an upfront amount of US$0.5 million and any future additional payments of up to US$14.1 million are contingent upon successful achievement of certain clinical data results as well as development, regulatory and commercial sales milestones. Cipher has no further financial obligations in respect of the Agreement if the applicable development and regulatory milestones outlined in the Agreement are not attained.
The Company will continue to collaborate with its partner Moberg as full results from their clinical trial become available, however this pipeline product does not impact the sales and earnings profile of Cipher's existing business today.
The Company continues to be focused on its recent acquisition of the NatrobaTM business from ParaPRO LLC as announced on July 29, 2024, as well as other potential growth opportunities. The Company believes the growth potential for the NatrobaTM product in the U.S. market and other markets internationally is significant, and the integration of this business into its existing profitable North American platform remains Cipher's focus and priority in the near term.